Three major randomized clinical trials and a meta-analysis have proved that for most men waiting for early signs of recurrence after prostatectomy (e.g., three consecutive PSA rises or a PSA of 0.1 ng/ml) to give radiation gave the same outcome as immediate (“adjuvant”) radiation (see this link). But there are exceptions. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvaant, earky, mortality, outcome, post-prostatectomy, risk, salvage | 2 Comments »
We didn’t expect to see data from the SPPORT trial for another 2 years, but the research team hit their recruitment goal early and have already been able to provide 5-year results. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: biochemical, clinical, post-prostatectomy, radiation, recurrence, salvage, SPPORT | 14 Comments »
After surgery, PSA should become “undetectable” on a normal PSA test (i.e., < 0.1 ng/ml) within a month or two, but sometimes it remains elevated. The primary purpose of the ARO 96-02 randomized clinical trial was to determine whether there was an advantage to treating stage T3-4N0 patients while PSA was still undetectable, or whether they could wait to be treated. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, detectable, immediate, post-prostatectomy, PSA, radiation, salvage | 24 Comments »
The concurrence of the Passover and Easter holidays this year appears to have limited medical science reports this weekend. There are really only two reports worth mentioning, and even they are of limited interest. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: "high risk", adjuvant therapy, immunotherapy, post-prostatectomy, vaccines | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 